Bisphosphonate Phytochemical Conjugates for Bone Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic bone disease and bone cancer, particularly those involving bisphosphonates, have limited effectiveness in improving patient survival and do not selectively target tumor cells within the bone microenvironment, necessitating the development of compounds with bone-targeting, antiproliferative, and anti-resorptive effects.
Innovation Solution
Development of compounds comprising a bisphosphonate moiety linked with a phytochemical, such as vitamin E derivatives, to target osteoclastic activity and promote osteoinductive effects, thereby inhibiting bone resorption and tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonate compounds are used for palliative treatment of skeletal related events, then bone resorption is inhibited, but patient survival shows minimal improvement
Solution Approach 1:
The patent combines a bisphosphonate moiety (which inhibits bone resorption) with a phytochemical moiety (which exhibits antiproliferative activity against tumor cells) into a single conjugate molecule. This merging allows the compound to simultaneously address bone resorption inhibition and tumor cell proliferation, thereby improving patient survival outcomes beyond what bisphosphonates alone can achieve
Solution Approach 2:
The conjugate compound performs multiple functions: the bisphosphonate portion targets osteoclastic activity to prevent bone loss, while the phytochemical portion directly kills tumor cells and prevents their proliferation. This multi-functionality allows a single agent to treat both the skeletal related events and the underlying cancer progression
2Reliability
If conventional treatments are used, then bone resorption is partially inhibited, but tumor cells within the bone microenvironment are not selectively targeted
Solution Approach 1:
The patent merges the bone-targeting bisphosphonate moiety with the tumor-cell-targeting phytochemical moiety into one conjugate, enabling selective accumulation at bone metastasis sites where it can simultaneously inhibit bone resorption and kill tumor cells, achieving both bone protection and selective tumor targeting
Solution Approach 2:
The conjugate compound exhibits local quality by concentrating its therapeutic effect specifically at the bone microenvironment where metastatic tumor cells are present. The bisphosphonate portion directs the molecule to bone tissue through its affinity for hydroxyapatite, while the phytochemical portion then exerts its antiproliferative effect locally on the tumor cells at that specific site
Data Source
AI summary
The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumors in the bone and surrounding tissues. Consequently the present invention provides compounds comprising a bisphosphonate moiety linked to a phytochemical, pharmaceutical compositions thereof and methods of treatment of bone diseases and/or proliferative disorders.